CAR-T cells targeting B7-H3 are also effective in inhibiting growth in vitro and in vivo of NSCLC (158), prostate cancer (159), glioblastoma (116), ovarian and triple negative breast cancer (160). Here, CD276 is linked to prostate cancer.